A review traces more than 5,000 years of male contraception, from early penile sheaths and the development of modern condoms and vasectomy to today's search for reversible alternatives. Researchers ar...

Researchers at Cornell University have made a significant advancement in male contraception by demonstrating a safe, reversible, nonhormonal method to temporarily halt sperm production. In a six-year mouse study, scientists used a small molecule called JQ1 to disrupt meiosis during prophase 1, a critical stage in sperm development. This intervention temporarily stopped sperm production without causing permanent harm. After cessation of treatment, normal sperm production resumed, and the mice were able to reproduce healthy offspring. While JQ1 itself is unsuitable for human use due to neurological side effects, the study provides proof that targeting meiosis could become a viable approach for male contraception. Unlike current options such as condoms or vasectomies, this method could offer long-lasting, reversible contraception without hormonal side effects. Potential delivery methods for humans could include injections every three months or transdermal patches. This breakthrough highlights a shift in contraceptive research toward nonhormonal methods that preserve overall reproductive health and fertility.

A groundbreaking male birth control pill, YCT-529, advances to the next stage of clinical trials, setting a new chapter in contraceptive options. Discover its progress, safety profile, and the impact on men's reproductive autonomy.

A groundbreaking male birth control pill, YCT-529, advances to the next stage of clinical trials, setting a new chapter in contraceptive options. Discover its progress, safety profile, and the impact on men's reproductive autonomy.